Company / R&D per Share
Gain Therapeutics, Inc. R&D per Share History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.71
FY2024
5-year range
$0.60 / $0.71
FY2021-FY2024
Trend
+0.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0.60 to $0.71 over the past 2 years.
Based on SEC 10-K filings.
0.71 in FY2024 with a 3-year CAGR of +3.7%.
Improved from $0.60 to $0.71 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +3.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, r&d per share increased 0.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.71 | +0.8% |
| FY2023 | $0.70 | +16.9% |
| FY2022 | $0.60 | -5.4% |
| FY2021 | $0.64 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026